Benjamin C Chaon1, Michael S Lee. 1. Department of Ophthalmology and Visual Neurosciences at the University of Minnesota, Minneapolis, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this study is to discuss current controversies surrounding the proposed treatments for traumatic optic neuropathy (TON) and review recent evidence from the literature relating to these therapeutic options. RECENT FINDINGS: No recent randomized controlled trials investigating surgical or medical interventions for TON exist. The current literature regarding treatment of TON consists mainly of small, mostly retrospective, observational studies. Treatment of TON with corticosteroids, surgical decompression of the optic canal or combinations of surgery and corticosteroids does not appear to offer improved visual outcomes compared with observation alone. Recent evidence suggests that there may be diminished functional reserve of the optic nerve following trauma. Novel neuroprotective therapies, such as erythropoietin, are currently under investigation in the treatment of TON. SUMMARY: TON may lead to profound visual disability. Because of the absence of Class I evidence relating to treatment of TON, a lack of consensus exists among clinicians regarding the appropriate treatment for TON. Our review of the recent literature finds that there is still no reliable evidence that treatment of TON with corticosteroids, surgical optic canal decompression or both confers any benefit over observation alone, and yet these interventions incur an additional risk that may not warrant their routine use.
PURPOSE OF REVIEW: The purpose of this study is to discuss current controversies surrounding the proposed treatments for traumatic optic neuropathy (TON) and review recent evidence from the literature relating to these therapeutic options. RECENT FINDINGS: No recent randomized controlled trials investigating surgical or medical interventions for TON exist. The current literature regarding treatment of TON consists mainly of small, mostly retrospective, observational studies. Treatment of TON with corticosteroids, surgical decompression of the optic canal or combinations of surgery and corticosteroids does not appear to offer improved visual outcomes compared with observation alone. Recent evidence suggests that there may be diminished functional reserve of the optic nerve following trauma. Novel neuroprotective therapies, such as erythropoietin, are currently under investigation in the treatment of TON. SUMMARY: TON may lead to profound visual disability. Because of the absence of Class I evidence relating to treatment of TON, a lack of consensus exists among clinicians regarding the appropriate treatment for TON. Our review of the recent literature finds that there is still no reliable evidence that treatment of TON with corticosteroids, surgical optic canal decompression or both confers any benefit over observation alone, and yet these interventions incur an additional risk that may not warrant their routine use.
Authors: Brian C Tse; Galina Dvoriantchikova; Wensi Tao; Ryan A Gallo; John Y Lee; Dmitry Ivanov; David T Tse; Daniel Pelaez Journal: Exp Eye Res Date: 2020-08-03 Impact factor: 3.467
Authors: Muhammad Nadeem; Adam Kindelin; Laura Mahady; Kanchan Bhatia; Md Nasrul Hoda; Andrew F Ducruet; Saif Ahmad Journal: Neuromolecular Med Date: 2020-11-13 Impact factor: 3.843
Authors: Wensi Tao; Galina Dvoriantchikova; Brian C Tse; Steven Pappas; Tsung-Han Chou; Manuel Tapia; Vittorio Porciatti; Dmitry Ivanov; David T Tse; Daniel Pelaez Journal: Sci Rep Date: 2017-09-18 Impact factor: 4.379
Authors: Chao Liu; Cheng-Wu Zhang; Yi Zhou; Wan Qing Wong; Liying Corinne Lee; Wei Yi Ong; Sung Ok Yoon; Wanjin Hong; Xin-Yuan Fu; Tuck Wah Soong; Edward H Koo; Lawrence W Stanton; Kah-Leong Lim; Zhi-Cheng Xiao; Gavin S Dawe Journal: Cell Death Differ Date: 2017-12-13 Impact factor: 15.828
Authors: Brian C Tse; Galina Dvoriantchikova; Wensi Tao; Ryan A Gallo; John Y Lee; Steven Pappas; Roberta Brambilla; Dmitry Ivanov; David T Tse; Daniel Pelaez Journal: Invest Ophthalmol Vis Sci Date: 2018-06-01 Impact factor: 4.799